This phase II clinical trial is evaluating whether adding KRC-01 injections to standard chemoradiotherapy may improve treatment outcomes in patients with locally advanced rectal cancer without metastases.
KRC-01 is an investigational product designed to improve the effectiveness of radiotherapy by increasing oxygen levels inside tumors, which may help radiation work better. KRC-01 contains hydrogen peroxide and sodium hyaluronate and is injected directly into the tumor before radiotherapy sessions.
Previous clinical experience in Japan, including studies in several types of cancer, suggested that this approach may improve tumor oxygenation and enhance the effect of radiotherapy.
The main objective of the K-BOOST study is to evaluate how many patients achieve a complete clinical response after treatment with chemoradiotherapy combined with intratumoral KRC-01 injections, potentially allowing some patients to avoid surgery. Surgery may still be recommended depending on the individual response to treatment.
Approximately 24 patients will participate in this multicenter French study. The experimental treatment period lasts approximately 26 weeks, and participants will be followed for up to 2 years.

开始日期2026-07-01

申办/合作机构

Gustave Roussy, Cancer Campus, Grand Paris

[+1]

CTIS2025-524378-40-00

/ Not yet recruiting临床2期IIT

Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)

开始日期2026-05-28

申办/合作机构

Institut Gustave Roussy EURL

NCT07534865

/ RecruitingN/AIIT

A Randomized, Parallel-Group, Controlled, Assessor-Blinded Clinical Trial of Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts

Hyperthermia treatment (hyperthermia) refers to treating diseases with temperature (39-45 ° C) beyond normal body temperature,. It has been reported that local warming at 44 ° C is able to effectively mobilize the body's immunity and clear HPV infected lesions, such as condyloma acuminatum and verruca vulgaris, etc. Significant progress has been made in the application of hyperthermia for viral skin diseases. Clinically, the addition of hydrogen peroxide solution can enhance the efficacy of hyperthermia in treating HPV infection. As a common transdermal drug delivery method, microneedles can increase drug penetration and thereby further improve treatment outcomes. Based on these findings, this study aims to explore an adjunctive approach to hyperthermia for treating viral warts to further enhance therapeutic efficacy.
This study employs a randomized, parallel-group, assessor-blinded design. Participants will be randomly assigned to three groups: hyperthermia alone, hyperthermia combined with microneedle patch (loaded with 0.9% saline), and hyperthermia combined with hydrogen peroxide microneedle patch (experimental group). An adaptive design will be adopted. The sample size is estimated at 70 participants per group, accounting for a potential 20% dropout rate. Interim analyses will be conducted during follow-up, and enrollment will be stopped when a positive result is reached for the primary efficacy endpoint (cure rate), at which point the sample size will be adjusted accordingly.

开始日期2026-05-01

申办/合作机构

中国医科大学附属第一医院

100 项与过氧化氢相关的临床结果

登录后查看更多信息

100 项与过氧化氢相关的转化医学

登录后查看更多信息

100 项与过氧化氢相关的专利（医药）

登录后查看更多信息

186,707

项与过氧化氢相关的文献（医药）

2026-09-01·Infection Disease & Health

Comparative efficacy of preprocedural mouthwashes in reducing microbial aerosols during dental procedures: A network meta-analysis

Review

作者: Xiao, Yang ; Lin, Yuwei ; Li, Enhong ; Yu, Xuefen ; Hong, Feiruo ; Zhou, Qiuyu

BACKGROUND:

This study aimed to evaluate and rank the efficacy of common preprocedural mouthwashes in reducing microbial aerosols during dental procedures via network meta-analysis (NMA) and provide evidence-based guidance for clinical infection control.

METHODS:

We systematically searched eight electronic databases from inception to February 2025. Randomized controlled trials (RCTs) assessing mouthwashes for reducing microbial aerosols during dental procedures were included. A Bayesian NMA with a random-effects model was performed. Risk of bias was assessed using the Cochrane tool, and the certainty of evidence was evaluated using the CINeMA framework. Surface under the cumulative ranking curve (SUCRA) and standardized mean difference (SMD) with 95% confidence interval (CI) were calculated to quantify intervention effects.

RESULTS:

Twenty-five RCTs involving 1111 participants and eight interventions were included. Compared with the control group, chlorhexidine (CHX) showed the largest effect (SMD = -7.10, 95% CI [-9.44, -4.73]), followed by herbal mouthwash (SMD = -5.16, 95% CI [-8.04, -2.17]) and povidone-iodine (PVP-I) (SMD = -4.57, 95% CI [-8.79, -0.21]). Efficacy ranking based on SUCRA values was as follows: CHX (0.90), cetylpyridinium chloride (CPC) (0.68), herbal mouthwash (0.61), PVP-I (0.53), essential oil mouthwash (0.44), normal saline (0.42), hydrogen peroxide (0.39), and control (0.03).

CONCLUSIONS:

CHX appears to be the most effective mouthwash for reducing microbial aerosols, with CPC and herbal mouthwashes as viable alternatives, particularly for patients with CHX intolerance or mucosal sensitivity. However, evidence for CPC is limited, and the overall certainty is low. Further well-designed RCTs are needed, especially to evaluate efficacy against viral aerosols.

2026-07-01·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY

Influence of Er:YAG laser activation and hydrogen peroxide concentration on esthetic efficacy, peroxide kinetics, diffusion, and thermal response during dental bleaching

Article

作者: Aidar, Karen Milaré Seicento ; Briso, André Luiz Fraga ; Junior, Fernando Costa ; Esteves, Lara Maria Bueno ; Silva, Marissa Geretti Timpurim ; Strazzi-Sahyon, Henrico Badaoui ; Correa, Jully Anna Cardoso ; Neto, Fernando Costa

BACKGROUND:

Laser-assisted in-office bleaching has been proposed to enhance whitening efficacy by accelerating hydrogen peroxide (H₂O₂) degradation and optimizing oxidative reactions. Nevertheless, Er:YAG laser influence on thermal behavior, peroxide kinetics, optical performance, and trans-amelodentinal diffusion remains insufficiently elucidated. Thus, this in-vitro study evaluated the combined effects of Er:YAG laser activation and different H₂O₂ gel concentrations on thermal, chemical, and optical responses during enamel bleaching.

METHODS:

186 bovine incisors were allocated into six groups according to H₂O₂ concentration (9%, 17.5%, and 35%) and Er:YAG irradiation (with or without activation). Phase I assessed temperature at the enamel surface and pulp chamber, and H₂O₂ degradation at distinct evaluation periods. Phase II evaluated chromatic alteration (ΔE₀₀), whitening index (WI_D) in relation to established perceptibility and acceptability thresholds, and trans-amelodentinal diffusion of H₂O₂. Statistical analyses were performed using ANOVA followed by Tukey post hoc tests (α = 0.05).

RESULTS:

Higher H₂O₂ concentrations resulted in significantly greater ΔE₀₀ and WI_D values; however, these effects were accompanied by increased temperature and peroxide diffusion. Notably, comparisons between the highest and lowest H₂O₂ gel concentrations, irrespective of laser irradiation, exceeded the established whitening perceptibility threshold. Er:YAG irradiation significantly accelerated H₂O₂ degradation and enhanced whitening outcomes compared with non-irradiated groups. Notably, laser activation reduced trans-amelodentinal peroxide diffusion across all evaluated H₂O₂ gel concentrations. Overall, reductions in temperature and H₂O₂ gel concentration were observed over time.

CONCLUSIONS:

Er:YAG-assisted bleaching modulates peroxide degradation kinetics, enhances whitening efficacy, and influences thermal and trans-amelodentinal peroxide diffusion.

2026-07-01·PLANT CELL AND ENVIRONMENT

Proteomic, Transcriptomic, Biochemical and Physiological Investigations Shed Light on Responses to Low Temperature Stress in Two Contrasting Soybean Varieties

Article

作者: Lin, Chuxin ; Bukhari, Birra ; Fang, Yuan ; Han, Yapeng ; Sun, Jin ; Guo, Changkui ; Lai, Xiancong ; Wang, Yingxiang

ABSTRACT:

Cold stress is the major abiotic factor limiting crop productivity. However, compared to model plant Arabidopsis Thaliana , crucial genes and underlying molecular mechanisms involved in soybean cold stress remain underexplored. Here, we investigate two national soybean cultivars, HH43 and HX3, bred from the northeast and southwest regions of China, which exhibit significant differences in cold tolerance. Morphological and biochemical examinations show that, compared to HH43, HX3 exhibits delayed wilting, reduced oxidative damage, and elevated antioxidant enzyme activities under low temperature (4°C). Transcriptomic analyses show distinct patterns between HH43 and HX3, in which HH43 displays a rapid gene response, while HX3 exhibits a gradual increase. Particularly, we identify MEblue and MEgreen modules related to cold stress and construct their GENIE3 networks. Key TFs such as ATAF1 and its potential targets were identified, which likely contribute to the cold tolerance differences between HH43 and HX3. Moreover, proteomic analyses reveal a broader and more sustained protein upregulation associated with maintaining metabolic activity and cellular homeostasis in cold‐tolerant HX3, while limited proteomic response was observed in cold‐sensitive HH43 and degradation of certain early responsive proteins. These findings provide substantial resources for further functional research and breeding cold‐tolerant soybean cultivars.

144

项与过氧化氢相关的新闻（医药）

2026-06-23

·GlobeNewswire-Health Care

TOMI Reports Accelerating SteraMist Adoption as Ebola Outbreaks and Global Biosecurity Threats Drive Preparedness Spending

Growing demand reflects increasing investment in scalable decontamination technologies across healthcare, emergency response, and critical infrastructure sectorsFREDERICK, Md., June 23, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination technologies, today announced continued growth in customer adoption and commercial demand for its SteraMist® platform as organizations worldwide expand preparedness efforts against emerging biological threats. Healthcare providers, emergency response agencies, transportation operators, and public health organizations are increasingly investing in advanced infection prevention capabilities as a growing number of pathogen outbreaks reinforce the need for long-term biosecurity infrastructure. Recent outbreaks of Ebola, measles, norovirus, and other highly contagious pathogens have highlighted the ongoing challenge of infectious disease containment. Public health experts increasingly view biosecurity preparedness as a permanent operational requirement rather than a temporary response to isolated events. According to public reports, recent Ebola outbreaks have expanded beyond their original regions and crossed international borders, underscoring the speed at which infectious disease threats can spread in a highly connected world. Governments and healthcare systems continue to invest heavily in preparedness programs designed to improve response capabilities before future outbreaks occur. Against this backdrop, TOMI has expanded deployments with healthcare providers, emergency response teams, and specialized pathogen programs. Internationally, an established partner has broadened SteraMist deployment across emergency medical transport and healthcare facilities to support high-consequence pathogen readiness. In the U.S., healthcare systems and federally supported preparedness programs are increasing adoption of SteraMist to strengthen environmental decontamination protocols. "We continue to see growing recognition that preparedness cannot begin after an outbreak occurs," said Dr. Halden Shane CEO of TOMI Environmental Solutions. "Organizations are investing ahead of potential threats, and they are looking for proven technologies that can be deployed rapidly, effectively, and at scale. We believe SteraMist is uniquely positioned to address that need." The global infection prevention and decontamination market continues to expand, driven by increasing awareness of healthcare-associated infections (HAIs), emerging pathogen risks, and stricter regulatory requirements. In the United States alone, HAIs impact approximately one in twenty-five hospital patients and are estimated to contribute tens of billions of dollars annually in healthcare costs. TOMI believes the growing focus on preparedness is creating a significant long-term opportunity for advanced decontamination technologies. As healthcare systems, government agencies, transportation networks, and critical infrastructure operators strengthen biosecurity protocols, scalable environmental disinfection solutions are becoming an increasingly important component of operational readiness. Looking ahead, TOMI sees additional opportunities to expand deployment through automation, robotics, and emerging autonomous delivery systems that could further enhance large-scale decontamination capabilities in hospitals, transportation hubs, public facilities, and emergency response scenarios. "We believe the future of biosecurity will require solutions capable of protecting large facilities and complex environments quickly and efficiently," added Dr. Shane. "Whether through traditional deployment models or future robotic and autonomous systems, the ability to disinfect at scale will become increasingly important." TOMI expects these industry trends to continue supporting commercial momentum throughout 2026 and beyond. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the life sciences sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Zach NevasIMS Investor Relations tomi@imsinvestorrelations.com

2026-06-17

·GlobeNewswire-Health Care

TOMI Advances Toward NSF Certification to Address Multi-Billion-Dollar Pharmaceutical, Biotech and Cleanroom Decontamination Markets

Certification process could position SteraMist® as a validated decontamination standard across biosafety cabinets, containment enclosures, cleanrooms, and life sciences facilities worldwideFREDERICK, Md., June 17, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced a major step toward achieving NSF certification for its patented SteraMist ionized Hydrogen Peroxide (iHP) technology, a milestone that could accelerate adoption across pharmaceutical manufacturing, biotechnology, cleanroom, biosafety, and laboratory markets worldwide. NSF International is a global, independent organization that develops public health standards and certifications to protect food, water, consumer products, and the environment. The initiative targets some of the fastest-growing sectors of the global contamination-control industry, including pharmaceutical production facilities, vaccine manufacturing operations, cell and gene therapy laboratories, biomedical research institutions, biosafety cabinets, and high-containment environments. Together, these markets represent billions of dollars in annual spending on contamination prevention, validation, and facility operations. As part of the certification process, TOMI and its strategic partner, Total Clean Air (TCA), will be presenting today before the NSF Joint Committee on Biosafety Cabinets. The presentation is designed to establish the framework for formal validation studies to test SteraMist iHP decontamination protocol across multiple types of biosafety cabinets (BSCs), that could ultimately lead to NSF certification of TOMI's SteraMist decontamination protocol. Management believes NSF certification would provide independent third-party validation of SteraMist's effectiveness, repeatability, and material compatibility, helping remove a significant barrier to adoption for highly regulated industries where validated decontamination procedures are critical. "Achieving NSF certification has the potential to be a transformative milestone for TOMI," said Elissa (E.J.) Shane, COO of TOMI Environmental Solutions. "This process is about much more than biosafety cabinets. It is about positioning SteraMist for broader adoption across pharmaceutical manufacturing, biotechnology, research laboratories, cleanrooms, and other mission-critical environments where contamination control is essential." The company believes certification could help streamline purchasing decisions for facility operators, biosafety officers, pharmaceutical manufacturers, and equipment providers by providing an independent industry-recognized validation standard. The certification may also facilitate broader relationships with biosafety cabinet manufacturers, cleanroom operators, validation consultants, and life sciences service providers. The global life sciences industry continues to invest heavily in contamination-control technologies driven by growth in biologics manufacturing, cell and gene therapy production, vaccine development, advanced research, and regulatory compliance requirements. TOMI believes SteraMist's rapid cycle times, broad-spectrum efficacy, and material compatibility position the technology to capitalize on these long-term industry trends. "Our objective is to establish SteraMist as a trusted decontamination solution across the life sciences ecosystem," Shane added. "NSF certification would represent an important step toward expanding our addressable market, accelerating adoption, and creating new recurring revenue opportunities across multiple high-value industry verticals." For more information about SteraMist and TOMI Environmental Solutions, visit SteraMist.com. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. About Total Clean Air Limited (TCA) Total Clean Air Limited (TCA) is a Somerset-based cleanroom engineering and contamination control specialist. The company provides end-to-end clean air solutions, including the design, engineering, construction, commissioning and validation of cleanrooms and controlled environments for highly regulated industries. Founded in 2018, the business draws on more than 50 years of combined industry experience and has delivered more than 200 cleanroom projects across the UK and internationally. Total Clean Air works with organisations operating in sectors including pharmaceuticals, biotechnology, aerospace, advanced manufacturing and scientific research. Total Clean Air is one of only two UKAS ISO 17025-accredited cleanroom constructors in the UK, supporting clients in achieving compliance with ISO, GMP and other globally recognised standards. Headquartered in Street, Somerset, the company serves clients across the UK, Europe and the Middle East. TCA won the accolade ‘Best Cleanroom Design & Construction Company 2026 – UK’ from Global Health Pharma (GHP) magazine in March 2026 and earned recognition as the Best Cleanroom, Clean Air and Containment Solutions Provider at the Corporate Excellence Awards 2023. Founded in 2018 and headquartered in Somerset, the company remains devoted to innovation, regulatory compliance, and exceptional customer satisfaction. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the life sciences sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Zach NevasIMS Investor Relations tomi@imsinvestorrelations.com

2026-06-11

·GlobeNewswire-Health Care

TOMI Environmental Solutions Highlights Massive Biosecurity Opportunity Ahead of FIFA World Cup

Largest Sporting Event in History Expected to Bring Millions of Travelers Across Three Countries, Highlighting Growing Need for Advanced Large-Scale Disinfection and Decontamination FREDERICK, Md., June 11, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced an update on its expanding global outreach, a significant increase in inbound market demand, and its strategic role in public health readiness ahead of historic international events. TOMI’s premier SteraMist iHP technology supports an elite, diverse customer base that includes healthcare coalitions, hospital networks, special pathogen units, and specialized medical transportation companies. SteraMist remains a critical component in worldwide outbreak mitigation, trusted by global health organizations to rapidly respond to volatile, emerging pathogens like Ebola, hantavirus, and norovirus. Driven by this ongoing demand, current frontline customers have actively increased their investments in system maintenance, training support, and TOMI’s proprietary BIT solution. TOMI has a strong history of capital adoption driven by public funding, with many emergency preparedness clients having previously utilized Ebola grants and emergency appropriations to secure SteraMist technology. TOMI has also seen increased interest from prospective clients worldwide looking to deploy SteraMist against these emerging global pathogens with an increase in biosecurity. In addition to global emerging pathogen defense, TOMI is seeing strong demand ahead of the FIFA World Cup in North America. With an estimated 6.5 million fans from over 100 countries attending the continent's largest-ever public gathering, healthcare facilities, stadiums, and hospitality networks are aggressively upgrading their sanitation protocols. Heightened awareness around highly contagious threats, such as measles, has prompted these healthcare entities with dedicated infection prevention funding to procure SteraMist systems. This proactive adoption establishes a superior standard of environmental safety during a period of unprecedented international travel. The World Cup may provide a glimpse into a much larger trend. As global travel continues to recover and major international events become larger and more complex, governments and facility operators are increasingly recognizing that biosecurity is becoming an essential component of public infrastructure. Just as airports invest in security screening, cities invest in emergency response systems, and governments maintain strategic reserves for national emergencies, many experts believe the coming decade could see significantly greater investment in biosecurity preparedness. The 2026 FIFA World Cup may be remembered not only as the largest sporting event ever staged, but also as a powerful reminder that in an increasingly connected world, scalable disinfection and decontamination capabilities are becoming critical infrastructure. For TOMI Environmental Solutions, that trend could represent a multi-billion-dollar long-term market opportunity extending far beyond healthcare into transportation, hospitality, food systems, public venues, critical infrastructure, defense, and large-scale public events. “Our mission has always been to provide a safer world, and right now, the global community is facing a unique intersection of emerging biological threats and unprecedented public gatherings,” said Dr. Halden Shane, Chief Executive Officer of TOMI. “The upcoming World Cup represents a massive logistical undertaking for North American infrastructure. With the targeted infection prevention funding, we are seeing proactive mobilization from healthcare systems. Our team is fully prepared to provide the technology, training, and BIT solution required to protect millions of visitors and staff. Remember that while the World Cup lasts only 39 days, the global biosecurity opportunity may last decades.” For more information about SteraMist and TOMI Environmental Solutions, visit SteraMist.com. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the emerging pathogen and commercial sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Zach Nevas IMS Investor Relations tomi@imsinvestorrelations.com

100 项与过氧化氢相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脂溢性角化病	美国	Aclaris Therapeutics, Inc.	2017-12-14
消毒剂	日本	Ebisu Yakuhin Kako KK	1986-03-01
伤口感染	中国	天津市东方广诚医药化工有限公司	1981-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寻常痤疮	临床3期	美国	Aclaris Therapeutics, Inc.	2018-09-17
疣	临床3期	美国	Aclaris Therapeutics, Inc.	2018-09-13
局部晚期直肠癌	临床2期	法国	KORTUC, Inc.	2026-07-01
复发性乳腺癌	临床2期	印度	KORTUC, Inc.	2020-06-16
复发性乳腺癌	临床2期	英国	KORTUC, Inc.	2020-06-16
局部晚期乳腺癌	临床2期	印度	KORTUC, Inc.	2020-06-16
局部晚期乳腺癌	临床2期	英国	KORTUC, Inc.	2020-06-16
黑色丘疹性皮病	临床2期	美国	Aclaris Therapeutics, Inc.	2017-06-26
可见病灶	临床2期	美国	Aclaris Therapeutics, Inc.	2017-06-26
局部晚期宫颈癌	临床1期	印度	KORTUC, Inc.	2026-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04659928 (CTgov)	临床4期	新型冠状病毒感染	41	High volume evacuation (HVE)+Hydrogen Peroxide (High Volume Evacuation (HVE) Suction Only and Hydrogen Peroxide)	艱繭觸鹹糧醖繭繭蓋築(鹹獵襯窪蓋繭蓋鬱膚積) = 艱獵鹹範觸夢膚遞憲憲製淵鬱繭鏇觸衊衊網壓 (選鏇餘鬱築鹹願鹹顧積, 16.38) 更多	-	2025-07-08
				Extraoral vacuum aspirator (EVA)+Hydrogen Peroxide (HVE Suction and Extraoral Vacuum Aspirator (EVA) and Hydrogen Peroxide)	艱繭觸鹹糧醖繭繭蓋築(鹹獵襯窪蓋繭蓋鬱膚積) = 鑰壓網觸膚蓋網餘網網製淵鬱繭鏇觸衊衊網壓 (選鏇餘鬱築鹹願鹹顧積, 155.43) 更多
ASTRO2024	N/A	直肠癌	-	Hydrogen Peroxide + Neoadjuvant Chemoradiotherapy	獵醖廠鑰糧鏇願齋構鏇(衊憲艱膚構獵網壓遞淵) = significantly more patients with grade 2 proctitis were observed in the IG (IG; 30%, HC; 0%; p<0.01) and 2 patients showed grade 2 hemorrhage in the IG but none in the HC 鹽鑰範襯餘衊築憲齋構 (觸廠鑰觸顧襯鑰蓋簾夢 ) 更多	-	2024-10-01
				Neoadjuvant Chemoradiotherapy
NCT03262701 (AHP, CTgov)	临床4期	慢性牙周炎	42	Hydrogen Peroxide (Hydrogen Peroxide Gel for 13weeks)	憲簾蓋鹽顧糧範選觸顧(構糧壓鹽膚艱顧觸憲夢) = 襯齋憲積簾壓顧鬱網鹹鑰蓋淵選構壓膚蓋網糧 (壓構積願鬱鑰壓淵齋網, 0.16) 更多	-	2022-12-21
				Hydrogen Peroxide (Hydrogen Peroxide Gel for 26weeks)	憲簾蓋鹽顧糧範選觸顧(構糧壓鹽膚艱顧觸憲夢) = 醖鏇範醖構繭築襯獵積鑰蓋淵選構壓膚蓋網糧 (壓構積願鬱鑰壓淵齋網, 0.05) 更多
NCT03812510 (CTgov)	临床3期	疣	426	hydrogen peroxide (A-101 45% (Active))	夢艱醖繭齋簾餘築繭膚 = 鹹夢鏇製膚鏇願衊選齋齋願壓範觸襯構齋齋網 (窪獵廠鬱壓繭鏇鑰憲鬱, 襯壓鹹繭築蓋廠簾範鑰 ~ 艱壓鏇築襯壓觸淵鏇繭) 更多	-	2020-11-23
				isopropyl alcohol (Isopropyl Alcohol and Water (Vehicle))	夢艱醖繭齋簾餘築繭膚 = 齋遞齋衊廠鹹壓積衊網齋願壓範觸襯構齋齋網 (窪獵廠鬱壓繭鏇鑰憲鬱, 餘窪襯糧鑰願餘糧醖積 ~ 餘鏇壓遞襯襯衊糧淵廠) 更多
NCT03687372 (CTgov)	临床3期	疣	503	vehicle	範築鏇艱築夢壓鏇齋壓(憲範簾艱膚衊壓願選鹽) = 壓網膚範淵製觸餘獵願選範範夢願鹹願鬱餘構 (餘獵鬱築餘憲鬱壓製遞, 憲憲鑰襯廠窪膚衊齋遞 ~ 鑰蓋艱積鹽夢夢鹽選醖) 更多	-	2020-10-05
NCT03691831 (CTgov)	临床3期	疣	502	Active (Active)	襯齋夢觸廠選鏇構製蓋 = 糧鏇膚選膚衊構鏇簾觸製廠鏇襯製襯齋獵獵顧 (鬱網獵憲構鑰遞醖餘壓, 觸窪鬱網憲遞簾鏇齋鹽 ~ 壓壓簾繭憲淵積顧襯窪) 更多	-	2020-10-05
				Vehicle (Vehicle)	襯齋夢觸廠選鏇構製蓋 = 鏇簾齋製願艱鏇淵膚觸製廠鏇襯製襯齋獵獵顧 (鬱網獵憲構鑰遞醖餘壓, 鬱夢積繭膚鑰繭範網鏇 ~ 淵糧鬱壓蓋襯顧齋選遞) 更多
NCT03224598 (CTgov)	临床2期	黑色丘疹性皮病	39	A-101 Topical Solution 40% (No Medical Abrading)	繭淵糧淵鬱觸積鏇蓋餘(艱淵製窪構鑰範餘遞廠) = 鹽範鑰觸範壓鬱壓蓋鏇夢膚廠構衊淵鏇衊構夢 (廠鹽鏇鬱網醖獵壓觸觸, 0.52) 更多	-	2020-03-17
				A-101 Topical Solution 40% (Medically Abrading)	繭淵糧淵鬱觸積鏇蓋餘(艱淵製窪構鑰範餘遞廠) = 壓夢簾鹽網夢構糧鑰獵夢膚廠構衊淵鏇衊構夢 (廠鹽鏇鬱網醖獵壓觸觸, 0.90) 更多
NCT03487588 (SK-FAN, CTgov)	临床4期	脂溢性角化病	41	A-101 Topical Solution	廠窪繭窪鏇積窪鹹選醖(積淵衊獵憲簾淵構壓鏇) = 積遞廠繭網糧鑰膚餘窪簾襯選壓範壓鏇網鹽糧 (餘構網壓築鬱衊築膚鹹, 0.62) 更多	-	2019-10-02
NCT03148691 (CTgov)	临床2期	脂溢性角化病	253	A-101 (Vehicle)	鑰築範製網鹽觸襯製願(窪醖窪製淵製鏇壓構衊) = 顧糧願鑰餘衊鏇鹹遞鬱鏇網鏇壓夢選遞鬱繭淵 (糧憲壓遞鹹積餘遞鏇衊, 10.4) 更多	-	2019-05-06
				A-101 (A-101 Low Dose)	鑰築範製網鹽觸襯製願(窪醖窪製淵製鏇壓構衊) = 淵顧夢廠壓鑰鹽廠鹹餘鏇網鏇壓夢選遞鬱繭淵 (糧憲壓遞鹹積餘遞鏇衊, 36.74) 更多
NCT03210337 (CTgov)	临床2期	疣	157	A-101 Topical Solution (Active)	憲襯獵製醖網獵獵製憲(膚範淵製範齋築鹹夢襯) = 壓網繭鬱製壓簾鏇糧夢夢窪窪鏇艱蓋觸獵窪構 (餘簾選網鏇淵憲簾憲廠, 0.85) 更多	-	2019-05-01
				A-101 Vehicle Solution (Vehicle)	憲襯獵製醖網獵獵製憲(膚範淵製範齋築鹹夢襯) = 製鬱獵膚網築願願獵衊夢窪窪鏇艱蓋觸獵窪構 (餘簾選網鏇淵憲簾憲廠, 0.49) 更多